 Lymphoma, Non-Hodgkin
"Lymphoma, Non-Hodgkin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Descriptor ID |
D008228
|
| MeSH Number(s) |
C04.557.386.480 C15.604.515.569.480 C20.683.515.761.480
|
| Concept/Terms |
Lymphoma, Non-Hodgkin- Lymphoma, Non-Hodgkin
- Lymphoma, Non Hodgkin
- Lymphoma, Atypical Diffuse Small Lymphoid
- Lymphoma, Non-Hodgkin's
- Lymphoma, Non Hodgkin's
- Lymphoma, Non-Hodgkin, Familial
- Lymphoma, Non-Hodgkins
- Lymphoma, Non Hodgkins
- Non-Hodgkins Lymphoma
- Small Cleaved-Cell Lymphoma, Diffuse
- Small Cleaved Cell Lymphoma, Diffuse
- Lymphoma, Nonhodgkins
- Nonhodgkins Lymphoma
- Lymphoma, Small Cleaved Cell, Diffuse
- Lymphoma, Small Cleaved-Cell, Diffuse
- Non-Hodgkin Lymphoma
- Non Hodgkin Lymphoma
- Non-Hodgkin's Lymphoma
- Non Hodgkin's Lymphoma
- Diffuse Small Cleaved-Cell Lymphoma
- Diffuse Small Cleaved Cell Lymphoma
- Lymphoma, Nonhodgkin's
- Lymphoma, Nonhodgkin
- Nonhodgkin's Lymphoma
Lymphoma, High-Grade- Lymphoma, High-Grade
- High-Grade Lymphoma
- High-Grade Lymphomas
- Lymphoma, High Grade
- Lymphomas, High-Grade
Lymphoma, Intermediate-Grade- Lymphoma, Intermediate-Grade
- Intermediate-Grade Lymphoma
- Intermediate-Grade Lymphomas
- Lymphoma, Intermediate Grade
- Lymphomas, Intermediate-Grade
Reticulum-Cell Sarcoma- Reticulum-Cell Sarcoma
- Reticulum-Cell Sarcomas
- Sarcomas, Reticulum-Cell
- Reticulum Cell Sarcoma
- Reticulosarcoma
- Reticulosarcomas
- Sarcoma, Reticulum-Cell
- Sarcoma, Reticulum Cell
Lymphoma, Mixed-Cell- Lymphoma, Mixed-Cell
- Lymphoma, Mixed Cell
- Lymphoma, Mixed Lymphocytic-Histiocytic
- Lymphocytic-Histiocytic Lymphoma, Mixed
- Lymphocytic-Histiocytic Lymphomas, Mixed
- Lymphoma, Mixed Lymphocytic Histiocytic
- Lymphomas, Mixed Lymphocytic-Histiocytic
- Mixed Lymphocytic-Histiocytic Lymphoma
- Mixed Lymphocytic-Histiocytic Lymphomas
- Mixed-Cell Lymphoma
- Lymphomas, Mixed-Cell
- Mixed Cell Lymphoma
- Mixed-Cell Lymphomas
- Lymphoma, Mixed
- Lymphomas, Mixed
- Mixed Lymphoma
- Mixed Lymphomas
Lymphoma, Mixed-Cell, Diffuse- Lymphoma, Mixed-Cell, Diffuse
- Diffuse Mixed-Cell Lymphoma
- Diffuse Mixed Cell Lymphoma
- Diffuse Mixed-Cell Lymphomas
- Lymphoma, Diffuse Mixed-Cell
- Lymphomas, Diffuse Mixed-Cell
- Mixed-Cell Lymphomas, Diffuse
- Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic
- Mixed-Cell Lymphoma, Diffuse
- Mixed Cell Lymphoma, Diffuse
- Lymphoma, Mixed Small and Large Cell, Diffuse
- Lymphoma, Small and Large Cleaved-Cell, Diffuse
- Mixed Small and Large Cell Lymphoma, Diffuse
- Diffuse Mixed Small and Large Cell Lymphoma
- Lymphoma, Mixed Cell, Diffuse
Lymphoma, Small Noncleaved-Cell- Lymphoma, Small Noncleaved-Cell
- Lymphoma, Small Noncleaved Cell
- Small Non-Cleaved-Cell Lymphoma
- Small Non Cleaved Cell Lymphoma
- Lymphoma, Small Non-Cleaved-Cell
- Lymphoma, Small Non Cleaved Cell
- Lymphomas, Small Non-Cleaved-Cell
- Non-Cleaved-Cell Lymphoma, Small
- Non-Cleaved-Cell Lymphomas, Small
- Small Non-Cleaved-Cell Lymphomas
- Diffuse Undifferentiated Lymphoma
- Diffuse Undifferentiated Lymphomas
- Lymphoma, Diffuse Undifferentiated
- Lymphomas, Diffuse Undifferentiated
- Undifferentiated Lymphoma, Diffuse
- Undifferentiated Lymphomas, Diffuse
- Lymphoma, Undifferentiated, Diffuse
- Small Noncleaved-Cell Lymphoma
- Lymphomas, Small Noncleaved-Cell
- Noncleaved-Cell Lymphoma, Small
- Noncleaved-Cell Lymphomas, Small
- Small Noncleaved Cell Lymphoma
- Small Noncleaved-Cell Lymphomas
Lymphoma, Undifferentiated- Lymphoma, Undifferentiated
- Undifferentiated Lymphoma
- Lymphomas, Undifferentiated
- Undifferentiated Lymphomas
- Lymphoma, Pleomorphic
- Lymphomas, Pleomorphic
- Pleomorphic Lymphoma
- Pleomorphic Lymphomas
Lymphoma, Diffuse- Lymphoma, Diffuse
- Diffuse Lymphoma
- Diffuse Lymphomas
- Lymphomas, Diffuse
- Lymphosarcoma
- Lymphosarcomas
- Sarcoma, Lymphatic
- Lymphatic Sarcoma
- Lymphatic Sarcomas
- Sarcomas, Lymphatic
Lymphoma, Low-Grade- Lymphoma, Low-Grade
- Low-Grade Lymphoma
- Low-Grade Lymphomas
- Lymphoma, Low Grade
- Lymphomas, Low-Grade
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Non-Hodgkin".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Non-Hodgkin".
This graph shows the total number of publications written about "Lymphoma, Non-Hodgkin" by people in this website by year, and whether "Lymphoma, Non-Hodgkin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 | | 1997 | 1 | 0 | 1 | | 1999 | 5 | 0 | 5 | | 2001 | 2 | 0 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 5 | 2 | 7 | | 2007 | 5 | 0 | 5 | | 2008 | 3 | 0 | 3 | | 2009 | 1 | 0 | 1 | | 2010 | 5 | 1 | 6 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 1 | 2 | | 2013 | 2 | 1 | 3 | | 2014 | 4 | 0 | 4 | | 2015 | 4 | 1 | 5 | | 2016 | 4 | 0 | 4 | | 2017 | 4 | 0 | 4 | | 2018 | 3 | 0 | 3 | | 2019 | 1 | 0 | 1 | | 2020 | 5 | 0 | 5 | | 2021 | 6 | 0 | 6 | | 2022 | 11 | 0 | 11 | | 2023 | 8 | 0 | 8 | | 2024 | 1 | 0 | 1 | | 2025 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, Non-Hodgkin" by people in Profiles.
-
Mestnik S, Marley AR, Lu Z, Turcotte LM, Marcotte E, Spector LG. Childhood body mass index at diagnosis and its association with non-Hodgkin lymphoma in the United States: a children's oncology group data analysis project. Leuk Lymphoma. 2025 Oct; 66(10):1931-1936.
-
Assouline SE, Mehta A, Hanel W, Doucet S, Johnston PB, Danilov A, Cooper BW, Chudnovsky A, Ding J, Long T, Stroopinsky D, Berg D, Alinari L. Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2025 Nov; 25(11):788-799.e11.
-
Kim TM, Lakhani NJ, Soumerai J, Kamdar M, Gainor JF, Messersmith W, Fanning P, Guan S, Jin F, Forgie A, Wan HI, Pons J, Randolph SS, Kim WS. Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study. Haematologica. 2025 Sep 01; 110(9):2102-2112.
-
Hwang SR, Godby RC, Negaard BJ, Mwangi R, Nedved AN, Barreto JN, Micallef IN, Ansell SM, Porrata L, Durani U, Thanarajasingam G, Habermann TM, Maurer MJ, Johnston PB, Khurana A. Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience. Blood Adv. 2025 Feb 25; 9(4):924-932.
-
Parikh RR, Milgrom SA, Campbell BA. Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1152-1158.
-
Zhang Y, Patel RP, Kim KH, Cho H, Jo JC, Jeong SH, Oh SY, Choi YS, Kim SH, Lee JH, Angelos M, Guruprasad P, Cohen I, Ugwuanyi O, Lee YG, Pajarillo R, Cho JH, Carturan A, Paruzzo L, Ghilardi G, Wang M, Kim S, Kim SM, Lee HJ, Park JH, Cui L, Lee TB, Hwang IS, Lee YH, Lee YJ, Porazzi P, Liu D, Lee Y, Kim JH, Lee JS, Yoon DH, Chung J, Ruella M. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study. Mol Cancer. 2023 12 09; 22(1):200.
-
Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Johnston PB, Ansell SM, Paludo J, Khurana A, Villasboas JC, Wang Y, Iqbal M, Moustafa MA, Murthy HS, Kharfan-Dabaja MA, Peterson JL, Hoppe BS. Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma. Haematologica. 2023 11 01; 108(11):2982-2992.
-
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood Adv. 2023 10 24; 7(20):6339-6350.
-
Knox A, Meyer M, Michener JL, Major A. The Great Imitator: Aggressive Non-Hodgkin Lymphoma Presenting as a Cervical Mass. Am J Med. 2024 02; 137(2):107-109.
-
Breen WG, Young JR, Hathcock MA, Kowalchuk RO, Thorpe MP, Bansal R, Khurana A, Bennani NN, Paludo J, Bisneto JV, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC, Lin Y. Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity. Blood Cancer J. 2023 08 18; 13(1):127.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|